secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K/A
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001601830-25-000142
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone
---------------------------------------------------------------------------

- Milestone triggered by initiation of GLP toxicology study on August 25, 2025.
- Issued 2,397,023 contingent shares at $5.2148/share, representing $12.5M value.
- Shares issued to Rallybio as seller under July 2025 ENPP1 JV acquisition.
- Prospectus supplement filed August 29, 2025 to register shares for resale.
- Filing amends prior 8-K from July 8, 2025 regarding the original acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000142/0001601830-25-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000142/rxrx-20250708.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer